机构:[a]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[b]China National Clinical Research Center for Neurological Diseases, Beijing, China[c]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[d]Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, China[e]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China 6 Tiantanxili, DongCheng District, Beijing 100050, China
The purpose of this study is to investigate the long-term outcomes after conservative and encephalodur oateriosynangiosis procedures for patients with moyamoya disease at late Suzuki stage. We retrospectively reviewed 64 patients (128 hemispheres) with moyamoya disease at late Suzuki Stage at Beijing Tiantan Hospital. Clinical features, radiologic findings, and outcomes were analyzed. The mean age at diagnosis was 29.0 +/- 14.9 years. The distribution of the initial Suzuki stage of MMD was as follows: stage 4, n = 75; stage 5, n = 46; stage 6, n = 7, PCA involvement was observed in 4 (37.5%) hemispheres. The incidence of postoperative stroke was 6.7%. During the average follow-up of 46.9 +/- 21.1 months, including postoperative and follow-up strokes, seven of 75 (9.3%) conservatively treated hemispheres and 10 of 87 (10.1%) surgically treated patients experienced a stroke event there was not statistically significant in the Kaplan-Meier curve of stroke incidence between the surgical group and conservative group (log-rank test, p = .848). However, the rate of perfusion improvement in indirect bypass surgically treated patients was higher than in those conservative treated patients 3 months after discharge (p < .05). Although indirect bypass surgery was shown to be effective in improving the cerebral perfusion in patients with MMD at late Suzuki stage, it failed to reduce the risk of recurrent stroke compared to conservative treatment. Further study is needed to determine whether direct bypass surgery is effective in MMD patients at late Suzuki stage. (c) 2017 Published by Elsevier Ltd.
基金:
National Science and Technology Major Project of China [2006BAI01A13, 2015BAI12B04]; Beijing Municipal Science and Technology CommissionBeijing Municipal Science & Technology Commission [Z13110200680000]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81371292]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150501]
第一作者机构:[a]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[b]China National Clinical Research Center for Neurological Diseases, Beijing, China[c]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[d]Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, China[e]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China 6 Tiantanxili, DongCheng District, Beijing 100050, China
共同第一作者:
通讯作者:
通讯机构:[a]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[b]China National Clinical Research Center for Neurological Diseases, Beijing, China[c]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[d]Beijing Translational Engineering Center for 3D Printer in Clinical Neuroscience, China[e]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China 6 Tiantanxili, DongCheng District, Beijing 100050, China
推荐引用方式(GB/T 7714):
Peicong Ge,Xun Ye,Qian Zhang,et al.Encephaloduroateriosynangiosis versus conservative treatment for patients with moyamoya disease at late Suzuki stage[J].JOURNAL OF CLINICAL NEUROSCIENCE.2018,50:277-280.doi:10.1016/j.jocn.2017.12.004.
APA:
Peicong Ge,Xun Ye,Qian Zhang,Dong Zhang,Shuo Wang&Jizong Zhao.(2018).Encephaloduroateriosynangiosis versus conservative treatment for patients with moyamoya disease at late Suzuki stage.JOURNAL OF CLINICAL NEUROSCIENCE,50,
MLA:
Peicong Ge,et al."Encephaloduroateriosynangiosis versus conservative treatment for patients with moyamoya disease at late Suzuki stage".JOURNAL OF CLINICAL NEUROSCIENCE 50.(2018):277-280